<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://oncdata.com/article/524cacd5-7d89-4c5f-9adc-097a21efa99d</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:49:27.198Z</news:publication_date><news:title>Real-World Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Squamous Urothelial Carcinoma</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/4f1d6a1d-4a40-46da-a34a-7096e2d5b9be</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:49:27.123Z</news:publication_date><news:title>Review: No Survival Difference With NACT Plus Surgery vs CRT in Cervical Cancer</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/9ecfecd7-c2ec-4d3f-9a4d-a7e3e374cb24</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T12:50:02.722Z</news:publication_date><news:title>Alectinib Yields 42% Major Pathologic Response in Stage III ALK-Positive NSCLC</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/5d59ec69-93e2-4968-8bb0-b5b466332d92</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T12:50:02.640Z</news:publication_date><news:title>Most Patients With Follicular Lymphoma on 5-Year Watch-And-Wait Remain Untreated</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/b59ef4d6-0036-4558-b2ff-b808b28c5f2f</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T02:49:21.030Z</news:publication_date><news:title>Enzalutamide Linked to Longer Time to CRPC Than Apalutamide in mCSPC Cohort</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/4c6a4a2b-abfd-437b-a4b7-093a4a826bbf</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T02:49:20.939Z</news:publication_date><news:title>International Guidelines for Localized Rectal Cancer</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/097dd1ba-c18e-46b7-bc10-d3e1359bca35</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:49:22.644Z</news:publication_date><news:title>Cost-Effectiveness of Dato-DXd vs Chemotherapy in Advanced Triple-Negative Breast Cancer</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/9b8f44bd-e0ea-4b50-a2fa-3583718aff0e</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:49:22.581Z</news:publication_date><news:title>Bayesian Reanalysis Finds High Probability of OS Benefit With [177Lu]Lu-PSMA-617 (Investigational)</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/5a13862c-8e21-4766-8118-450bf236b770</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T12:49:57.984Z</news:publication_date><news:title>Evidence Is Insufficient to Show MPNST Surveillance Improves Outcomes in NF1: Review</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/59af50bb-9979-4d3a-92ad-8b2419ea1fad</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T12:49:57.882Z</news:publication_date><news:title>Phase I Trial of CD19 CAR-T Cells With PD1/CD28 Switch Receptor in R/R B-Cell Lymphoma</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/8113d491-eab7-4f1c-9b99-2cbbfdfaca68</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T02:49:20.711Z</news:publication_date><news:title>Th17-Based Model and Biomarkers Stratify Severe irAE Risk in Advanced NSCLC</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/c6e1146a-52cc-4852-a82c-f3ada730e28e</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T02:49:20.570Z</news:publication_date><news:title>TACE Plus Immunotherapy Versus TACE Alone in Unresectable Hepatocellular Carcinoma</news:title></news:news></url>
</urlset>